Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design by Lisanne S. Rigter et al.
STUDY PROTOCOL Open Access
Colorectal cancer surveillance in Hodgkin
lymphoma survivors at increased risk of
therapy-related colorectal cancer: study
design
Lisanne S. Rigter1, Manon C. W. Spaander2, Leon M. Moons3, Tanya M. Bisseling4, Berthe M. P. Aleman5,
Jan Paul de Boer6, Pieternella J. Lugtenburg7, Cecile P. M. Janus8, Eefke J. Petersen9, Judith M. Roesink10,
John M. M. Raemaekers11, Richard W. M. van der Maazen12, Annemieke Cats1, Eveline M. A. Bleiker13,
Petur Snaebjornsson14, Beatriz Carvalho14, Iris Lansdorp-Vogelaar15, Katarzyna Jóźwiak16, Hein te Riele17,
Gerrit A. Meijer14, Flora E. van Leeuwen16 and Monique E. van Leerdam1*
Abstract
Background: Second primary malignancies are a major cause of excess morbidity and mortality in cancer
survivors. Hodgkin lymphoma survivors who were treated with infradiaphragmatic radiotherapy and/or
high-dose procarbazine have an increased risk to develop colorectal cancer.
Colonoscopy surveillance plays an important role in colorectal cancer prevention by removal of the precursor lesions
(adenomas) and early detection of cancer, resulting in improved survival rates. Therefore, Hodgkin lymphoma survivors
treated with infradiaphragmatic radiotherapy and/or high-dose procarbazine could benefit from colonoscopy, or other
surveillance modalities, which are expected to reduce colorectal cancer incidence and mortality. Current knowledge
on clinicopathological and molecular characteristics of therapy-related colorectal cancer is limited. The pathogenesis
of such colorectal cancers might be different from the pathogenesis in the general population and therefore these
patients might require a different clinical approach.
We designed a study with the primary aim to assess the diagnostic yield of a first surveillance colonoscopy
among Hodgkin lymphoma survivors at increased risk of colorectal cancer and to compare these results
with different screening modalities in the general population. Secondary aims include assessment of the
test characteristics of stool tests and evaluation of burden, acceptance and satisfaction of CRC surveillance
through two questionnaires.
Methods/Design: This prospective multicenter cohort study will include Hodgkin lymphoma survivors who
survived ≥8 years after treatment with infradiaphragmatic radiotherapy and/or procarbazine (planned inclusion of 259
participants). Study procedures will consist of a surveillance colonoscopy with removal of precursor lesions (adenomas)
and 6–8 normal colonic tissue biopsies, a fecal immunochemical test and a stool DNA test. All neoplastic lesions
encountered will be classified using relevant histomorphological, immunohistochemical and molecular analyses in
order to obtain more insight into colorectal carcinogenesis in Hodgkin lymphoma survivors. The Miscan-model will be
used for cost-effectiveness analyses.
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Discussion: Evaluation of the diagnostic performance, patient acceptance and burden of colorectal cancer surveillance
is necessary for future implementation of an individualized colorectal cancer surveillance program for Hodgkin
lymphoma survivors. In addition, more insight into treatment-induced colorectal carcinogenesis will provide
the first step towards prevention and personalized treatment. This information may be extrapolated to other
groups of cancer survivors.
Trial registration: Registered at the Dutch Trial Registry (NTR): NTR4961.
Keywords: Hodgkin lymphoma, Surveillance, Colonoscopy, Colorectal neoplasia, Stool (DNA) test, Carcinogenesis
Background
Colorectal cancer risk in cancer survivors
Because of the improvements of cancer treatment over
recent decades, cancer survival has greatly increased. A
major and serious complication of cancer treatment is
the occurrence of second primary malignancies, which
accounts for approximately 18% of all cancers in the
Western world [1, 2]. The development of second
primary malignancies is influenced by multiple factors,
including genetic predisposition, environmental factors
and lifestyle factors. Moreover, certain anticancer treat-
ments have the (paradoxical) capability to cause cancer,
due to mutagenic and genome destabilizing effects.
Hodgkin lymphoma (HL) survivors have a substantial
excess risk of developing colorectal cancer (CRC) [3–8].
The risk of CRC is also increased in survivors of many
other malignancies, including survivors of testicular can-
cer, Wilms tumor, central nervous system malignancies
and bone cancer [6–9]. The excess risk of CRC is
strongly related to primary cancer treatment with radio-
therapy or alkylating agents [5, 7, 8, 10]. A recent ana-
lysis of a Dutch multicenter HL cohort showed an
increased incidence of CRC in long-term survivors of
HL compared with the general population (SIR 2.4 (95%
CI 1.8–3.2). HL survivors who were treated with high
dose (>4.2 g/m2) procarbazine, or with infradiaphrag-
matic radiotherapy in combination with chemotherapy
have an even higher risk (SIR 4.3 (95% CI 2.9–6.1) and
5.7 (95% CI 3.7–8.2), respectively) [3, 5].
Colorectal cancer surveillance
HL survivors have a clearly increased risk of developing
CRC for a prolonged period, starting 10 years up to over
30 years after receiving infradiaphragmatic radiotherapy
and/or procarbazine [5]. These HL survivors may there-
fore benefit from a CRC surveillance program. Colonos-
copy surveillance is important for CRC prevention in
high-risk populations by early detection and removal of
the precursor lesions (adenomas) with malignant poten-
tial, resulting in improved survival rates [11–13].
Surveillance programs in high-risk groups are different
from screening programs in the general population, for
which the fecal occult blood test-based program is the
method of choice in the European Union [14]. However,
the fecal occult blood test is inadequate for high-risk
populations because of the relatively low sensitivity for
advanced adenomas.
In the Netherlands, surveillance is performed in spe-
cific high-risk populations, like those with familial CRC
or Lynch syndrome [15]. In current Dutch clinical prac-
tice, no colonoscopy surveillance program exists for HL
survivors at high risk of CRC, because important
requirements for screening/surveillance are not met, i.e.
the presence of a recognizable latent stage of disease
and knowledge of natural history. The pattern of devel-
opment of a precursor lesion into cancer has substantial
influence on the preventive effects of colonoscopy
surveillance, and this pattern is unknown for CRCs that
develop in HL survivors. Flat adenomas in the presence
of chronic radiation colitis have been described in case
reports on cancer survivors [16, 17]. In addition, a re-
cent review reported a high frequency of mucinous
adenocarcinomas in case reports on radiotherapy-
associated rectal cancer, suggesting a difference in tumor
biology as compared with sporadic CRCs [18].
It is thus important to personalize CRC prevention
programs for different subgroups.
Because of the high risk of CRC in HL survivors, and
the lack of data on the pathogenesis of these cancers, we
designed a prospective cohort study that evaluates diag-
nostic yield and test characteristics of colonoscopy sur-
veillance in HL survivors. These characteristics will also
be evaluated for stool tests. In addition, the cost-
effectiveness and patient perception of CRC surveillance
will be evaluated. This knowledge could lead to a per-
sonalized CRC surveillance program for HL survivors.
Methods
Objectives
The objective of this study is to provide information
on the potential benefit of a personalized CRC sur-
veillance program for HL survivors at increased risk
of developing CRC.
The primary aim is to assess the diagnostic yield of
advanced colorectal neoplasia detected by colonoscopy
among HL survivors at increased risk of CRC. Advanced
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colorectal neoplasia is defined as an adenoma with high
grade dysplasia, ≥25% villous component or ≥10 mm
diameter or CRC.
Secondary aims are to assess the test characteristics of
stool tests (fecal immunochemical test (FIT), and stool
DNA (sDNA test)) and to examine patient perception
(burden, acceptance and satisfaction) and cost-
effectiveness of CRC surveillance in HL survivors. In
addition, the clinicopathological and molecular charac-
teristics of therapy-related colorectal neoplasia will be
evaluated.
The Medical Ethics Committee of the Netherlands
Cancer Institute approved this study protocol and the




This prospective multicenter cohort study will include
patients from a large cohort of HL survivors who
were treated for HL after 1965. HL treatment data
and follow-up data were collected as previously
described [3, 5, 19, 20].
Patients who meet the inclusion criteria will be invited
for study participation in one of the Dutch study centers
(The Netherlands Cancer Institute, Amsterdam, Erasmus
MC, University Medical Center, Rotterdam, University
Medical Center Utrecht, Utrecht and Radboud Univer-
sity Medical Center, Nijmegen). The inclusion criteria
consist of the treatment of primary or recurrent HL con-
sisting of at least one of the following treatments:
1. infradiaphragmatic radiotherapy consisting of at
least para-aortic and iliac fields
2. chemotherapy containing a cumulative procarbazine
dose of ≥2.8 g/m2
3. infradiaphragmatic radiotherapy (any field (s)) and
chemotherapy (any regimen)
Additional inclusion criteria are HL diagnosis at the
age of 16–50 years, survival of at least 8 years after this
treatment, current age of 25 years or older and life ex-
pectancy of 5 years or more. Patients who meet one of
the following criteria will be excluded: proctocolectomy,
colonoscopy surveillance for other indications (including
hereditary CRC syndrome, familial CRC syndrome, in-
flammatory bowel disease, colorectal adenoma, history
of CRC), colonoscopy in the past 5 years, on-going cyto-
toxic treatment or radiotherapy for malignant disease,
coagulopathy (prothrombin time > 50% of control; partial
thromboplastin time > 50 s) or anticoagulants (vitamin K
antagonists or new oral anticoagulants) that cannot be
stopped, comorbidity leading to an impaired physical
performance (World Health Organization performance
status 3–4) or mental retardation and no informed
consent.
The population of HL survivors in the four participat-
ing centers consists of approximately 850 eligible partici-
pants. Patients will be invited by their treating physician,
either a radiation oncologist or a medical oncologist/
hemato-oncologist. When patients are no longer under
surveillance, they will be invited to a lymphoma Sur-
vivorship Care Clinic to inform them about the risk of
late effects of Hodgkin lymphoma treatment and to per-
form surveillance according to standardized follow-up
guidelines [21]. These Survivorship Care Clinics are be-
ing set up by a national consortium i.e. the BETER con-
sortium (Better care after HL, Evaluation of long-term
Treatment Effects and screening Recommendations).
This consortium aims to reduce morbidity and mortality
of late adverse effects of HL treatment by a survivorship
care program in order to improve life expectancy and
quality of life of HL survivors. At the Survivorship Care
Clinic, eligible participants will be invited for participa-
tion in this CRC surveillance research project.
Control population
For the diagnostic yield of colonoscopy, FIT and sDNA
test, comparison with the asymptomatic Dutch general
population will be performed using the data of the
COCOS study [22]. In this study primary colonoscopy
screening was performed in 1276 asymptomatic individ-
uals out of 5924 randomly selected invitees between 50
and 75 years of age. Advanced neoplasia (defined as an
adenoma with high grade dysplasia, ≥25% villous com-
ponent or ≥10 mm diameter or CRC) was detected in
9% of individuals in this population. 1256/1276 individ-
uals also performed a FIT and 1060/1276 collected a
feces sample for a sDNA test [23].
For the molecular profile, data will be compared with
the Dutch general population using existing data of
sporadic CRC under the age of 70 years [24].
Sample size calculation
The main endpoint of the study is the diagnostic yield of
advanced colorectal neoplasia among HL survivors
detected by surveillance colonoscopy, which will be
compared with the diagnostic yield performed in the
general population [22].
Based on a 9% prevalence of advanced colorectal
neoplasia in the asymptomatic general population, an
increase to 15% of more in HL survivors after adjust-
ment for age would be a significant change. To detect
such a difference with 80% power, we need to include at
least 259 study participants (based on the two-sided test
for two independent proportions with 5% significance
level). An interim analysis will be performed after the in-
clusion of 100 participants. At this point, when the
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detected prevalence of advanced colorectal neoplasia in
the study population is 30% or higher, the difference
between the two groups will be considered significant
with a power of 80% and alpha level of 0.0006 (based on
the group-sequential tests for two proportions).
Cost-effectiveness analyses
We will use the well-established microsimulation
screening analysis (MISCAN) model to determine the
cost-effectiveness of colonoscopy, FIT and sDNA test
surveillance in HL survivors compared to FIT screen-
ing, e.g. the Dutch CRC screening program [25–28].
This MISCAN model will be performed to estimate
the size of health benefits and costs of a surveillance
program. In this mathematical model, a large number of
fictitious individual life histories are simulated in each of
which several colorectal lesions can emerge. The influ-
ence of the implementation of a surveillance program
will be simulated, which can change some of the life
histories.
This model will be able to estimate incidence, preva-
lence and mortality of CRC, and the results and effects
of surveillance. The costs and the number of life-years
gained for the population with and without the imple-
mentation of surveillance will be calculated.
The MISCAN model will be used to estimate the
optimal time of initiation, interval and frequency of
colonoscopies. These results will be used for the CRC
surveillance recommendation in HL survivors.
Study procedures
Colonoscopy
All patients will receive oral and standard written infor-
mation about the preparation and the colonoscopy by
their treating physician or by the gastroenterologist. The
preparation will be performed as for routine colonos-
copy by ingesting a commonly prescribed oral electrolyte
lavage solution. Standard methods of conscious sedation
(midazolam and/or fentanyl citrate or propofol) and
cardiopulmonary monitoring will be used during the
procedure. The colonoscopy will be performed by expe-
rienced gastroenterologists (>1000 colonoscopies and
certified for performing colonoscopies in the Dutch
population-based CRC screening program). Quality
measures of colonoscopy will include registration of
location of deepest insertion, withdrawal time, quality of
preparation (Boston scale), colonoscopy difficulty (5-
point scale), patient discomfort (Gloucester comfort
scale) and level of sedation (Leeds score).
In the presence of colorectal neoplasia, polypectomy
will be performed or biopsies will be taken according to
standard protocol. The following data will be collected
concerning colorectal neoplasia: number, morphology
(Paris classification), size (measured with an open biopsy
forceps), location (cecum, ascending, hepatic flexure,
transverse, splenic flexure descending, sigmoid or rec-
tum) and details about the polypectomy.
In the presence of a polyp of ≥10 mm, field biopsies
will be taken and a fragment of the polyp will be allo-
cated for study purposes after routine pathological
evaluation. Four biopsies of normal mucosa of the trans-
verse colon and two to four biopsies of normal mucosa
of the descending colon will be taken (in both patients
who did and who did not receive infradiaphragmatic
irradiation). The transverse colon is the colonic segment
that usually receives the highest dose of irradiation in
infradiaphragmatic radiotherapy, whereas the descending
colon receives a low dose of irradiation. In case of an
additional surgical resection of a neoplastic lesion, part
of the resection specimen will be allocated for study pur-
poses. Study material will be stored at the participating
hospitals and shipped to the Netherlands Cancer Insti-
tute for analyses.
Histology, immunohistochemistry and molecular pathology
Routine histological evaluation of all colorectal neoplasia
will be performed by experienced gastro-intestinal
pathologists. Immunohistochemical and molecular ana-
lyses will be performed on advanced neoplastic lesions.
The advanced colorectal neoplasia will be immunohisto-
chemically stained for the presence of mismatch repair
proteins (MLH1, MSH2, MSH6 and PMS2). DNA will
be isolated and microsatellite instability analysis will be
performed using a standard Pentaplex PCR kit. A multi-
plex ligation-dependent probe amplification kit will be
used to assess the CpG island methylator phenotype,
which detects the methylation status of promoter re-
gions of 8 different genes (CACNA1G, CDKN2A,
CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and
SOCS1). Mutation analysis of KRAS and BRAF will be
performed by using Sequenome MassArray and/or high-
resolution melting and sequencing. Further analyses of
the advanced neoplastic lesions will depend on the re-
sults of an ongoing study on a retrospective cohort of
CRCs in HL survivors.
Biopsies
The characteristics of the colonic mucosa biopsies in
both the transverse and descending colon will be ana-
lyzed and stratified by treatment to evaluate the effect of
irradiation on endoscopic normal mucosa. These ana-
lyses will depend on the results of abovementioned ana-
lyses, and will include the evaluation of mismatch repair
function.
Questionnaires
The participant will be sent the first questionnaire prior
to colonoscopy. This questionnaire will evaluate risk
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factors for CRC other than prior cancer treatment, the
physical and mental functioning of the patient (EQ-5D,
cancer worry scale, hospital anxiety and depression
scale) and the expected burden of colonoscopy.
The second questionnaire will be sent to the partici-
pant a week after the colonoscopy. This questionnaire
will include questions about the physical and mental
functioning of the patient (EQ-5D, cancer worry scale,
hospital anxiety and depression scale) and the experi-
enced burden of colonoscopy. The questionnaires on the
expected burden and experienced burden will consist of
information on the mental and physical burden, includ-
ing embarrassment and pain during both the bowel
preparation and the colonoscopy procedure. The burden
of colonoscopy will be compared with the burden of a
colonoscopy in the general population [29].
Stool tests
A whole stool sample will be collected and a FIT will be
performed on the sample. The whole-stool samples will
be collected in a dedicated collection kit (Exact Sciences
corporation, Madison, USA), which includes a buffer to
stabilize and preserve the sample that will be taken prior
to the start of bowel preparation for the surveillance col-
onoscopy. All kits will need to be at the laboratory for
analysis within 72 h after sample production. Samples
that are received after this time interval will be excluded
from the study. Samples will be homogenized, aliquoted
and stored at −80 °C.
The stool tests will include a FIT and a sDNA test for
the detection of methylation and mutation markers. The
sensitivity, specificity, positive predictive value and nega-
tive predictive value will be calculated using the colonos-
copy as a reference standard. Also, results will be
compared to the detection rates in the asymptomatic
general population [23].
Discussion
This protocol describes a multicenter prospective cohort
study that assesses the value of colonoscopy surveillance
and the additional value of FIT and sDNA tests in a
high-risk population of HL survivors. For the develop-
ment of a personalized surveillance program, we need to
evaluate the diagnostic yield, test characteristics, patient
perception and cost-effectiveness of various methods
(i.e. colonoscopy, FIT, sDNA). The study is currently on-
going and is expected to complete inclusion of partici-
pants at the end of 2017.
Colonoscopy screening programs are implemented in
the general population in many countries, and intensi-
fied personalized surveillance programs exist for various
high-risk groups.
The pattern of development of a precursor lesion into
cancer has substantial influence on the preventive effects
of colonoscopy surveillance. The most common pathway
of the development of CRC is through a protrude polyp-
oid neoplastic lesion that can easily be detected and
resected endoscopically. Nevertheless, a subset of pre-
cursor lesions is easily missed and/or difficult to resect,
e.g. sessile or flat lesions, or dysplastic foci like those
that occur in inflammatory bowel disease [30]. Also,
microsatellite instable tumors are likely to develop
through an accelerated growth pattern that emphasizes
the need for a higher frequency of surveillance [31].
Because of these differences in development of a pre-
cursor lesion into cancer and the differences in CRCs
risks, each high-risk group surveillance recommendation
includes specific characteristics (e.g. starting age, fre-
quency and technique).
Most cancer survivors at increased risk of therapy-
related CRC are not aware of their increased CRC
risk and do not receive CRC surveillance. The Ameri-
can Children’s Oncology Group (COG) recommends
colonoscopy surveillance in survivors of childhood
cancer who received at least 30 Gray of abdominal
radiotherapy, starting 10 years after radiotherapy or at
the age of 35 (whichever occurs last) and repeating
every 5 years [24]. The Dutch lymphoma survivor
consortium and childhood cancer survivor consor-
tium, however, did not include CRC surveillance in
their guidelines because of the absence of existing
data for this specific category of patients. Evidence is
lacking for CRC risk stratification of HL survivors,
and it is not known if the pathogenesis of radiation-
and chemotherapy-induced CRCs is similar to the
pathogenesis of CRC in the general population [18,
32]. In addition, the COG recommendation is limited
to childhood cancer survivors and it does not include
survivors who have been treated with chemotherapy,
but only with abdominal radiotherapy [3, 7, 10, 33].
Also, the effectiveness of surveillance according to
this recommendation is not clear, and Daniel et al.
reported that the adherence to this recommendation
was less than 30% [34].
HL survivors have an increased risk of developing
CRC for a prolonged period in their lives, [5] which
makes CRC surveillance in this population likely
beneficial. Not all studies show comparable increased
CRC risks in survivors of various cancer types, in-
cluding HL. However, these studies frequently lacked
follow-up time (<10 years) and/or stratification for
treatment differences, e.g. treatment regimen and dos-
age. This may have led to an underestimation of the
risk of CRC in cancer survivors who were treated
with infradiaphragmatic irradiation and/or alkylating
agents [5, 7, 8, 10].
There is little information on the clinical characteris-
tics of therapy-related CRC. Youn et al. compared the
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survival of first primary CRC patients with 70 stage II-
IV colon cancer patients who were treated for HL. After
adjusting for stage, overall survival and CRC-specific
survival were reduced in the small population of HL sur-
vivors (HR 1.46 (95% CI 1.1–2.0) and HR 1.37 (95% CI
0.96–1.96), respectively) [8]. In addition to the excess
risk of morbidity and mortality caused by CRC, HL sur-
vivors have an increased risk of cardiovascular disease
and other second malignant neoplasms [4, 20]. The
population that will benefit from CRC surveillance may
therefore be smaller than expected because of these
competing risks.
In addition to the insight into the therapy-related
colorectal carcinogenesis that will be obtained in the
present study, we are currently performing a retro-
spective study on the histopathological and molecular
characteristics of therapy-related CRC already diag-
nosed in the HL survivor cohort [3, 5]. The results
of this study will influence the analyses on the
advanced colorectal neoplasia detected in this
prospective study.
In conclusion, this protocol describes a prospective
cohort study that evaluates diagnostic yield of advanced
colorectal neoplasia, the most optimal surveillance
method, patient acceptance and cost-effectiveness of
CRC surveillance in HL survivors. The results will pro-
vide necessary information for the development of a per-
sonalized CRC surveillance program in this high-risk
population. This information may be extrapolated to
other groups of cancer survivors at increased risk of
CRC, such as childhood cancer survivors [8, 10]. The
incidence of advanced colorectal neoplasia over time
cannot be evaluated, because this CRC surveillance
study is limited to a first colonoscopy. Therefore, we
intend to perform a follow-up study to evaluate a second
surveillance round.
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